Four of six patients continuing on study and significant reduction in CA-125 observed-- --Phase 1b portion of the study is now open for enrollment-- CAMBRIDGE, MA - June 27, 2013 - Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the completion of the dose escalation ... (more)
http://www.drugs.com/clinical_trials/verastem-successfully-completes-phase-1-stage-combination-trial-cancer-stem-cell-inhibitor-vs-6063-15813.html?
http://www.drugs.com/clinical_trials/verastem-successfully-completes-phase-1-stage-combination-trial-cancer-stem-cell-inhibitor-vs-6063-15813.html?
No comments:
Post a Comment